These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36708129)

  • 41. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study.
    Chang Y; Cho YK; Kim Y; Sung E; Ahn J; Jung HS; Yun KE; Shin H; Ryu S
    Hepatology; 2019 Jan; 69(1):64-75. PubMed ID: 30019340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-alcoholic fatty liver disease.
    Powell EE; Wong VW; Rinella M
    Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis.
    Di Ciaula A; Bonfrate L; Krawczyk M; Frühbeck G; Portincasa P
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease.
    Chhatwal J; Dalgic OO; Chen W; Samur S; Bethea ED; Xiao J; Hur C; Corey KE; Loomba R
    JAMA Netw Open; 2022 Sep; 5(9):e2230426. PubMed ID: 36098969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study.
    Prabhakar T; Kaushal K; Prasad M; Gupta E; Sood A; Jain AK; Shukla A; Goel A; Duseja A; Saraya A; Shah S; Kumar G; Sarin SK
    Hepatol Int; 2023 Jun; 17(3):745-752. PubMed ID: 36940070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
    Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
    Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
    J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies.
    Marventano S; Salomone F; Godos J; Pluchinotta F; Del Rio D; Mistretta A; Grosso G
    Clin Nutr; 2016 Dec; 35(6):1269-1281. PubMed ID: 27060021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography.
    Xiao J; Ng CH; Chan KE; Tang ASP; Teh R; Ling AHZ; Yong JN; Lim WH; Tan DJH; Tan C; Win KM; Bwa AH; Chew NWS; Huang D; Dan YY; Noureddin M; Siddiqui MS; Sanyal A; Tamaki N; Muthiah M
    Scand J Gastroenterol; 2023 Jan; 58(1):76-82. PubMed ID: 35944527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of alcohol consumption on nonalcoholic fatty liver disease.
    Weng G; Dunn W
    Transl Gastroenterol Hepatol; 2019; 4():70. PubMed ID: 31620652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis.
    Sánchez-Jiménez BA; Brizuela-Alcántara D; Ramos-Ostos MH; Alva-López LF; Uribe-Esquivel M; Chávez-Tapia NC
    Alcohol; 2018 Jun; 69():63-67. PubMed ID: 29660603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study.
    Rice BA; Naimi TS; Long MT
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2854-2863.e2. PubMed ID: 36503167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
    Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
    Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.
    Berkan-Kawińska A; Piekarska A
    Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714
    [No Abstract]   [Full Text] [Related]  

  • 56. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.
    Tokushige K; Hashimoto E; Horie Y; Taniai M; Higuchi S
    J Gastroenterol; 2011 Oct; 46(10):1230-7. PubMed ID: 21748549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Thongtan T; Deb A; Vutthikraivit W; Laoveeravat P; Mingbunjerdsuk T; Islam S; Islam E
    Indian J Gastroenterol; 2022 Apr; 41(2):119-126. PubMed ID: 35318571
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.